Navigation Links
Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
Date:6/5/2008

thy volunteers to the CAD patient population," stated Doug Gooding, Chief Executive Officer of Regado Biosciences. "Following the completion of a Phase 1 program in a total of 173 patients, the Company now is evaluating this first-in-class antidote-reversible therapeutic system in a Phase 2a trial in patients undergoing elective percutaneous coronary intervention. If the results of this study further confirm the Phase 1 data, we are confident this system may be able to transform the way anticoagulation is approached in coronary revascularization procedures and other acute care settings."

Data from Regado's Phase 1b study were presented previously at the American Heart Association's 2007 Scientific Sessions.

About REG1 Anticoagulation System Clinical Program

Regado's Phase 1 program included three studies. A Phase 1a study enrolled 84 healthy volunteers, while the Phase 1b study reported above enrolled 50 patients with stable coronary artery disease who were receiving aspirin with or without clopidogrel. In addition, the Company conducted a Phase 1c clinical study, in which 39 healthy volunteers were randomized to receive either three consecutive REG1 treatment cycles or placebo. The Phase 1c study further demonstrated RB007's ability to reverse the anticoagulant effect of RB006 either completely or partially, depending on the level of dosing of RB007.

Based upon the combined results of the Company's Phase 1a, 1b, and 1c studies, Regado initiated REVERSAL-PCI, a multi-center, open-label, randomized Phase 2a clinical study of the REG1 anticoagulation system. The Phase 2a study is enrolling 26 patients undergoing elective percutaneous coronary intervention (PCI) to assess whether REG1 can replace standard heparin therapy during the performance of coronary balloon angioplasty dilatation and stenting in patients at low risk for complications associated with therapy-related bleeding or heart attack.

About REG1 Anticoagulation System


'/>"/>
SOURCE Regado Biosciences
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
2. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
3. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
4. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
5. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
6. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
7. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
8. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
9. Neurocrine Biosciences Reports First Quarter 2008 Results
10. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
11. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  Restore Health, a leading personalized medicine company ... it is now offering pharmacogenetics testing that provides ... upon their particular genetic makeup. Comprehensive medication management ... a patient,s genetics and their entire drug regimen.  ... this new service to healthcare providers and their ...
(Date:7/24/2014)... , and MARSEILLE, France , ... , Exclusive global license from University of Tokyo enables ... sequencing (NGS) gene panels, for blood cancers  ... test, indicate favorable prognosis for patients with bone marrow ... potential for developing companion diagnostics to guide treatment with ...
(Date:7/24/2014)... July 24, 2014  Abaxis, Inc. (NasdaqGS: ... analysis systems, today reported financial results for the first ... quarter overview: , Revenues of $47.5 million, up ... EPS of $0.21, up 50% over last year,s comparable ... revenues of $7.2 million, up 20% over last year,s ...
Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11
... One of the most difficult-to-remove tumors located deep in ... the work of one Los Angeles surgeon. Hrayr Shahinian ... Los Angeles, has developed a minimally invasive approach to removing ... procedure is expected to replace the more invasive open brain ...
... 18 For some people with ongoing or chronic pain, ... difference between disability and the ability to function at near-normal ... surgery or injury, sound pain management with opioids can speed ... medications and carry risks when they are not used properly. ...
Cached Medicine Technology:Dr. Hrayr Shahinian of the Skull Base Institute Develops Revolutionary Endoscopic Procedure 2Opioid Education Lags as Abuse Climbs 2Opioid Education Lags as Abuse Climbs 3
(Date:7/25/2014)... 25, 2014 (HealthDay News) -- The human brain can ... dehydration, a new study finds. Although dehydration ... England have found that the brain compensates by increasing ... "This research has helped us understand a lot ... exercise in extreme conditions," study first author Steven Trangmar, ...
(Date:7/25/2014)... Ticket Down is a reliable source for ... at California Memorial Stadium. With the post-World Cup emotions ... organizers of the 2014 Guinness International Champions Cup have brought ... With teams representing La Liga, English Premier League, Serie A, ... best football players from around the world to 12 American ...
(Date:7/25/2014)... TX (PRWEB) July 25, 2014 ... the current state of the Galactooligosaccharides (GOS) ... a basic overview of the industry, including definitions, ... and Chinese domestic market analysis are provided with ... landscape of the market. A comparison between the ...
(Date:7/25/2014)... FRIDAY, July 25, 2014 (HealthDay News) -- Babies seem ... suggests. By the time women are 34 weeks ... of their mother,s voice reciting a familiar nursery rhyme, ... predominant source of sensory stimulation in the developing fetus," ... University of Florida,s College of Nursing, said in a ...
(Date:7/25/2014)... July 25, 2014 Newyorktermlifeinsurance.org has ... life insurance plans and traditional policies. , The ... clients make between no medical exam life insurance plans ... types of life insurance plans to provide a simple ... life insurance plans can now be purchased online. Although ...
Breaking Medicine News(10 mins):Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 2Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 3Health News:Rhymes Reveal Evidence of Learning in the Womb 2Health News:No Medical Exam Life Insurance and Traditional Plans - Newyorktermlifeinsurance.org Provides Quotes for All Types of Life Insurance 2
... VIEJO, Calif., Feb. 25 The Ensign,Group, ... company of the Ensign(TM) group of,skilled nursing, ... that GE Healthcare Financial Services has expanded,Ensign,s ... it an,additional five years., (Logo: ...
... WASHINGTON, Feb. 25 House Republican Whip,Roy Blunt ... legislation that will be introduced by Republican Leader ... in an effort to put,Medicare on a path ... sorely needed reforms to put,Medicare on a path ...
... for Medicare Advantage,Plans Sold to Senior Citizens, ... today that it will require UnitedHealth Group Inc.,(United) ... assets relating,to United,s Medicare Advantage business in the ... acquisition of Sierra. The Department said that the,transaction, ...
... L. Mitchell, M.D., M.P.H., of Hebrew SeniorLifes Institute ... with advanced dementia are frequently prescribed antibiotic medications, ... practice raises concerns about the end-of-life care of ... as the emergence of antimicrobial resistance. The paper ...
... place burden on Medicare, analysis finds , , MONDAY, Feb. ... Americans newly diagnosed with heart failure has declined, the ... new research finds. , The Duke University study analyzed ... diagnosed with heart failure between 1994 and 2003. It ...
... to increase the risk that women will have abnormal ... effectiveness of both methods for detecting breast cancer, according ... Archives of Internal Medicine, one of the JAMA/Archives journals. ... at the Los Angeles Biomedical Research Institute at Harbor-UCLA ...
Cached Medicine News:Health News:The Ensign Group Establishes $50 Million Credit Facility with GE Healthcare Financial Services 2Health News:Justice Department Requires Divestiture in UnitedHealth Group's Acquisition of Sierra Health Services 2Health News:Justice Department Requires Divestiture in UnitedHealth Group's Acquisition of Sierra Health Services 3Health News:Hebrew SeniorLife researcher finds 2Health News:Hebrew SeniorLife researcher finds 3Health News:More Elderly Americans Living With Heart Failure 2Health News:LA BioMed study finds hormone therapy increases frequency of abnormal mammograms, breast biopsies 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: